On September 14, 2026, BlackRock, Inc. acquired 2.63 million H shares of HENGRUI PHARMA (01276) by way of taking a security interest in shares off-exchange, with consideration being non-cash assets. The transaction was not matched on the SEHK open market and therefore not a direct secondary-market dealing.
Prior to the acquisition, BlackRock, Inc.'s long position in HENGRUI PHARMA was 17.20 million shares, representing 6.66%; following the acquisition, the holding changed to 19.83 million shares, with the long position ratio rising to 7.68%.